ALIGNMENTS

Sequence Comparison "A"

```
RESULT 1
AAY99372
ID   AAY99372 standard; Protein; 331 AA.
XX
AC   AAY99372;
XX
DT   08-AUG-2000  (first entry)
XX
DE   Human PRO1430.(UNQ736) amino acid sequence SEQ ID NO:116.
XX
KW   Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
KW   transmembrane; secretion; immunoadhesion; pharmaceutical; screening.
XX
OS   Homo sapiens.
XX
PN   WO200012708-A2.
XX
PD   09-MAR-2000.
XX
PF   01-SEP-1999;   99WO-US20111.
XX
PR   01-SEP-1998;   98US-0098716.
PR   01-SEP-1998;   98US-0098749.
PR   01-SEP-1998;   98US-0098750.
PR   02-SEP-1998;   98US-0098803.
PR   02-SEP-1998;   98US-0098821.
PR   02-SEP-1998;   98US-0098843.
PR   09-SEP-1998;   98US-0099536.
PR   09-SEP-1998;   98US-0099596.
PR   09-SEP-1998;   98US-0099598.
PR   09-SEP-1998;   98US-0099602.
PR   09-SEP-1998;   98US-0099642.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker K,  Goddard A,  Gurney AL,  Smith V,  Watanabe CK,  Wood WI;
XX
DR   WPI; 2000-237871/20.
DR   N-PSDB; AAA37054.
XX
PT   New mammalian DNA sequences encoding transmembrane, receptor or
PT   secreted PRO polypeptides, useful for screening of potential peptide or
PT   small molecule inhibitors of the relevant receptor/ligand interactions
XX
PS   Claim 12; Fig 66; 773pp; English.
XX
CC   AAA37022 to AAA37144 encode the new isolated human transmembrane,
CC   receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The
CC   transmembrane and receptor PRO proteins can be used for screening of
CC   potential peptide or small molecule inhibitors of the relevant
CC   receptor/ligand interactions. The polypeptides and nucleotide sequences
CC   encoding then have various industrial applications, including uses as
CC   pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent
CC   PCR primers and hybridisation probes used in the isolation of the PRO
CC   polypeptides from the present invention.
XX
SQ   Sequence   331 AA;

  Query Match           100.0%;  Score 1695;  DB 21;  Length 331;
  Best Local Similarity  100.0%;  Pred. No. 4.5e-166;
  Matches  331;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MSRYLLPLSALGTVAGAAVLLKDYVTGGACPSKATIPGKTVIVTGANTGIGKQTALELAR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MSRYLLPLSALGTVAGAAVLLKDYVTGGACPSKATIPGKTVIVTGANTGIGKQTALELAR 60

Qy         61 RGGNIILACRDMEKCEAAAKDIRGETLNHHVNARHLDLASLKSIREFAAKIIEEEERVDI 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RGGNIILACRDMEKCEAAAKDIRGETLNHHVNARHLDLASLKSIREFAAKIIEEEERVDI 120

Qy        121 LINNAGVMRCPHWTTEDGFEMQFGVNHLGHFLLTNLLLDKLKASAPSRIINLSSLAHVAG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LINNAGVMRCPHWTTEDGFEMQFGVNHLGHFLLTNLLLDKLKASAPSRIINLSSLAHVAG 180

Qy        181 HIDFDDLNWQTRKYNTKAAYCQSKLAIVLFTKELSRRLQGSGVTVNALHPGVARTELGRH 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 HIDFDDLNWQTRKYNTKAAYCQSKLAIVLFTKELSRRLQGSGVTVNALHPGVARTELGRH 240

Qy        241 TGIHGSTFSSTTLGPIFWLLVKSPELAAQPSTYLAVAEELADVSGKYFDGLKQKAPAPEA 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TGIHGSTFSSTTLGPIFWLLVKSPELAAQPSTYLAVAEELADVSGKYFDGLKQKAPAPEA 300

Qy        301 EDEEVARRLWAESARLVGLEAPSVREQPLPR 331
              ||||||||||||||||||||||||||||||
Db        301 EDEEVARRLWAESARLVGLEAPSVREQPLPR 331
```

Sequence Comparison "B"

```
RESULT 2
AAE05174
ID   AAE05174 standard; Protein; 331 AA.
XX
AC   AAE05174;
XX
DT   12-SEP-2001 (first entry)
XX
DE   Human drug metabolising enzyme (DME-5) protein.
XX
KW   Human; drug metabolising enzyme; DME-5; immunosuppressive; gene therapy;
KW   cytostatic; autoimmune disorder; inflammatory disorder; atherosclerosis;
KW   osteoporosis; eye disorder; hepatic tumour; Addison's disease; cretinism;
KW   rheumatoid arthritis; acquired immune deficiency syndrome; AIDS; anaemia;
KW   developmental disorder; endocrine disorder; iritis; acromegaly; epilepsy;
KW   thyrotoxicosis; pancreatic disorder; diabetes mellitus; obesity; adenoma;
KW   gastrointestinal disorder; nodular hyperplasia; conjunctivitis; glaucoma;
KW   actinic keratosis; metabolic disorder; dysphagia; anorexia; carcinoma;
KW   cell proliferative disorder.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..17
FT                   /label= Signal_peptide
FT   Protein         18..331
FT                   /note= "Mature drug metabolising enzyme (DME-5) protein"
XX
PN   WO200151638-A2.
XX
PD   19-JUL-2001.
XX
PF   12-JAN-2001; 2001WO-US01174.
XX
PR   14-JAN-2000; 2000US-0176139.
PR   21-JAN-2000; 2000US-0177443.
PR   28-JAN-2000; 2000US-0178574.
XX
PA   (INCY-) INCYTE GENOMICS INC.
XX
PI   Yang J, Baughn MR, Burford N, Au-Young J, Lu DAM, Reddy R;
PI   Ring HZ, Hillman JL, Yue H, Azimzai Y, Yao MG, Gandhi AR;
PI   Nguyen DB, Tang YT, Lal P, Bandman O;
XX
DR   WPI; 2001-425874/45.
DR   N-PSDB; AAD09940.
XX
PT   Drug metabolizing enzymes and encoding polynucleotides, useful for
PT   diagnosing, treating and/or preventing autoimmune, inflammatory, cell
PT   proliferative, developmental, endocrine, eye, metabolic, and
PT   gastrointestinal disorders -
XX
PS   Claim 1; Page 139-140; 133pp; English.

XX
CC   The present sequence is human drug metabolising enzyme (DME-5) protein.
CC   Human DME and its nucleic acid molecule are useful for the diagnosis,
CC   treatment and prevention of disorders associated with increased or
CC   decreased expression of DME. Examples of such disorders include,
CC   autoimmune/inflammatory disorder such as acquired immune deficiency
CC   syndrome (AIDS), rheumatoid arthritis, osteoporosis; cell proliferative
CC   disorder such as actinic keratosis, atherosclerosis; developmental
CC   disorder such as epilepsy, anaemia; endocrine disorder such as
CC   acromegaly, cretinism, thyrotoxicosis; pancreatic disorder such as
CC   diabetes mellitus; eye disorder such as conjunctivitis, glaucoma, iritis;
CC   metabolic disorder such as Addison's disease, obesity; gastrointestinal
CC   disorder such as anorexia, dysphagia and hepatic tumours including
CC   nodular hyperplasia, adenomas and carcinomas. DME DNA is useful for
CC   creating 'knockin' humanised animals (pigs) or transgenic animals (mice
CC   or rats) to model human disease. DME DNA is also in useful is gene
CC   therapy. DME and its immunogenic fragments are useful for screening
CC   libraries of compounds in several drug screening assays.
XX
SQ   Sequence   331 AA;

  Query Match           100.0%;  Score 1695;  DB 22;  Length 331;
  Best Local Similarity  100.0%;  Pred. No. 4.5e-166;
  Matches  331;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MSRYLLPLSALGTVAGAAVLLKDYVTGGACPSKATIPGKTVIVTGANTGIGKQTALELAR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MSRYLLPLSALGTVAGAAVLLKDYVTGGACPSKATIPGKTVIVTGANTGIGKQTALELAR 60

Qy         61 RGGNIILACRDMEKCEAAAKDIRGETLNHHVNARHLDLASLKSIREFAAKIIEEEERVDI 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 RGGNIILACRDMEKCEAAAKDIRGETLNHHVNARHLDLASLKSIREFAAKIIEEEERVDI 120

Qy        121 LINNAGVMRCPHWTTEDGFEMQFGVNHLGHFLLTNLLLDKLKASAPSRIINLSSLAHVAG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LINNAGVMRCPHWTTEDGFEMQFGVNHLGHFLLTNLLLDKLKASAPSRIINLSSLAHVAG 180

Qy        181 HIDPDDLNWQTRKYNTKAAYCQSKLAIVLFTKELSRRLQGSGVTVNALHPGVARTELGRH 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 HIDPDDLNWQTRKYNTKAAYCQSKLAIVLFTKELSRRLQGSGVTVNALHPGVARTELGRH 240

Qy        241 TGIHGSTFSSTTLGPIFWLLVKSPELAAQPSTYLAVAEELADVSGKYFDGLKQKAPAPEA 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TGIHGSTFSSTTLGPIFWLLVKSPELAAQPSTYLAVAEELADVSGKYFDGLKQKAPAPEA 300

Qy        301 EDEEVARRLWAESARLVGLEAPSVREQPLPR 331
              ||||||||||||||||||||||||||||||
Db        301 EDEEVARRLWAESARLVGLEAPSVREQPLPR 331
```